The revenue beat and maintained guidance are positive, but the large GAAP EPS miss and management's admission that Q1 was 'a bit light to internal expectations' create near-term uncertainty. Watch for weekly prescription data and Q2 2026 revenue trajectory to validate the late March/April acceleration. The path to Q3 profitability is the key catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 30 $11.20entry
- T+1 · 7mo ago +7.23%α +7.01% · $12.01
- T+5 · 6mo ago +13.13%α +11.40% · $12.67
- T+20 · 6mo ago −7.86%α −12.82% · $10.32
- T+60 · 4mo ago +6.70%α +3.59% · $11.95
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Phathom reported Q1 2026 revenue of $58.3M (+104% YoY), beating the $56.8M consensus, but GAAP EPS of -$0.37 missed the -$0.19 consensus. The company maintained FY 2026 guidance of $320-$345M revenue and expects operating profitability (ex-stock comp) starting Q3 2026. Prescription trends strengthened in late March/April, but the EPS miss and 'light to internal expectations' commentary temper the top-line beat.
Key Financial Metrics
Key Facts
- Q1 2026 net revenue $58.3M vs $28.5M YoY (+104%), above $56.8M consensus
- GAAP EPS -$0.37 vs consensus -$0.19 (miss of -94.7%)
- Non-GAAP adjusted net loss per share -$0.18 vs -$1.07 YoY
- FY 2026 guidance maintained: revenue $320-$345M, non-GAAP opex $235-$255M
- Operating profitability (ex-stock comp) expected Q3 2026 and full year 2026
- 268,000 total VOQUEZNA prescriptions filled in Q1 (+115% YoY)
- Cash and equivalents $180.9M; net cash usage ~$15M in Q1
- Phase 2 EoE trial topline results expected late Q4 2026 or early Q1 2027
Financial Impact
Revenue beat by ~$1.5M (2.6%) but GAAP EPS missed by -$0.18 (94.7% miss vs consensus). Non-GAAP adjusted net loss improved to -$14.7M from -$77.1M YoY.
Risk Factors
- GAAP EPS miss of -94.7% vs consensus may spook momentum traders
- Q1 was 'light to internal expectations' despite 104% YoY revenue growth
- Gross-to-net discount of 55-59% remains high, pressuring net revenue per script
- Cash runway depends on achieving operating profitability by Q3 2026 as guided
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3284660 |
Track record
16 reports on PHAT
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +36.43% at T+60 after the Jul 30, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $6.28 Now $5.88 −6.37% settles Nov 18
- Nov 2, 202614d ago SC 13D/A Neutral 3/10 Entry $5.74 to $5.45 Now $5.88 +2.44% ▼ −5.14% −4.55% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 5/10 Entry $6.22 to $5.08 Now $5.88 −5.47% ▼ −18.33% −13.60% vs SPY
- Oct 26, 202621d ago 8-K Bearish 5/10 Entry $5.94 to $5.74 Now $5.88 +1.01% ▲ +3.37% +2.11% vs SPY
- Oct 23, 202624d ago 8-K Bearish 6/10 Entry $5.94 to $5.74 Now $5.88 +1.01% ▲ +3.37% +2.11% vs SPY
- Oct 19, 202628d ago Press Release Neutral 1/10 Entry $7.01 Now $5.88 −16.12% No price data
- Sep 29, 20266w ago 8-K Neutral 4/10 Entry $7.30 to $6.81 Now $5.88 −19.45% ▼ −6.71% −8.63% vs SPY
- Jul 30, 202615w ago 8-K Mixed 5/10 No price data
- Jul 30, 202615w ago Press Release Bearish 6/10 Entry $9.03 to $8.39 Now $5.88 +34.88% ▲ +7.09% +10.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers